Engineers Gate Manager LP Cassava Sciences Inc Transaction History

Engineers Gate Manager LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.64 - $30.11 $470,827 - $1.12 Million	37,249 New	37,249 $838,000
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $321,143 - $498,827	13,689 New	13,689 $330,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $245,543 - $399,572	-7,532 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $276,951 - $684,734	7,532 New	7,532 $329,000
Q2 2021 Aug 16, 2021	SELL	$32.15 - $89.72 $495,753 - $1.38 Million	-15,420 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $109,327 - $1.36 Million	15,420 New	15,420 $693,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.